Liver cancer trial aims to shrink tumors before surgery with immune booster
NCT ID NCT07268131
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests whether combining a liver-directed procedure (TACE) with an immunotherapy drug (QL1706) before surgery, followed by more immunotherapy after surgery, can help patients with liver cancer that is too large or numerous for standard transplant criteria. The study will enroll 30 adults with resectable BCLC stage A or B hepatocellular carcinoma. The main goal is to see if at least 90% of the tumor is killed or shrunk by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
QL1706 (a combination of two immune-boosting drugs, iparomlimab and tuvonralimab) plus transarterial chemoembolization (TACE)
What this could lead to
If successful, this approach could improve the chance of eliminating liver tumors before surgery and reduce the risk of cancer returning afterward.
What could go wrong
This is a small, early-phase trial with only 30 participants, so results may not apply to everyone. The combination of TACE and immunotherapy can cause serious side effects, and it is not yet known if it will improve long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.